RBX1 and COVID-19: Recently, lenalidomide, a CRBN/RBX1 inhibitor, has shown protective roles in multiple COVID-19–infected myeloma patients against progression into severe infections [37], which suggests the emergence of this particular platelet subpopulation may drive the disease severity in COVID-19 infection.